English	French	Notes	Complete/Exclude
FIRST COURSE OF TREATMENT - RADIATION			
38. REGIONAL DOSE (cGy)...........: 			
39. BOOST DOSE (cGy)..............: 			
40. INTRA-OPERATIVE RADIATION			
41. CONCURRENT CHEMOTHERAPY.......: 			
FIRST COURSE OF TREATMENT - CHEMOTHERAPY			
42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
43. INTRAPERITONEAL CHEMOTHERAPY..: 			
44. CHEMOTHERAPEUTIC TOXICITY.....: 			
45. CHEMOTHERAPY/SURGERY SEQUENCE.: 			
FIRST COURSE OF TREATMENT - IMMUNOTHERAPY			
46. ADMINISTRATION OF INTERFERON..: 			
TREATMENT COMPLICATIONS			
CASE REGISTRATION			
48. INITIALS OF CASE ABSTRACTOR...: 			
49. DATE CASE WAS ABSTRACTED......: 			
The Accession Year is not 2000.			
2000 Patient Care Evaluation Study of Hepatocellular Cancers			
1. FACILITY ID NUMBER (FIN)			
5. PLACE OF BIRTH			
6. DATE OF BIRTH			
8. SPANISH ORIGIN			
10. PRIMARY PAYER AT DIAGNOSIS			
 1. FACILITY ID NUMBER (FIN)			
 5. PLACE OF BIRTH			
 6. DATE OF BIRTH			
 8. SPANISH ORIGIN			
  1. FACILITY ID NUMBER (FIN)......: 			
  2. ACCESSION NUMBER..............: 			
  3. SEQUENCE NUMBER...............: 			
9  4. POSTAL CODE AT DIAGNOSIS......			
7  5. PLACE OF BIRTH................			
  6. DATE OF BIRTH.................: 			
9  8. SPANISH ORIGIN................			
18 10. PRIMARY PAYER AT DIAGNOSIS....			
11. CLASS OF CASE			
13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS			
14. ALCOHOL CONSUMPTION			
15. TUMOR MARKERS			
16. TESTS RELATED TO LIVER FUNCTION			
17. RADIOLOGICAL EVALUATION			
18. DEFINITIVE DIAGNOSIS			
19. DATE OF INITIAL DIAGNOSIS			
22. DIAGNOSTIC CONFIRMATION			
 TUMOR IDENTIFICATION			
 11. CLASS OF CASE.................: 			
1000      ORAL CONTRACEPTIVES..........			
1001      ESTROGEN REPLACEMENT.........			
 13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS:			
1012 14. ALCOHOL CONSUMPTION...........			
 15. TUMOR MARKERS:			
 16. TESTS RELATED TO LIVER FUNCTION:			
 17. RADIOLOGICAL EVALUATION:			
     CT ARTERIAL PORTOGRAPHY:			
1022      VASCULAR INVASION............			
1023      BILOBAR DISEASE..............			
1024      LYMPH NODES..................			
1025      SIZE OF DOMINANT TUMOR (mm)..			
1026      NUMBER OF TUMORS.............			
     SPIRAL CT:			
1029      VASCULAR INVASION............			
1030      BILOBAR DISEASE..............			
1031      LYMPH NODES..................			
1032      SIZE OF DOMINANT TUMOR (mm)..			
1033      NUMBER OF TUMORS.............			
     INCREMENTAL CT:			
1036      VASCULAR INVASION............			
1037      BILOBAR DISEASE..............			
1038      LYMPH NODES..................			
1039      SIZE OF DOMINANT TUMOR (mm)..			
1040      NUMBER OF TUMORS.............			
1043      VASCULAR INVASION............			
1044      BILOBAR DISEASE..............			
1045      LYMPH NODES..................			
1046      SIZE OF DOMINANT TUMOR (mm)..			
1047      NUMBER OF TUMORS.............			
1050      VASCULAR INVASION............			
1051      BILOBAR DISEASE..............			
1052      LYMPH NODES..................			
1053      SIZE OF DOMINANT TUMOR (mm)..			
1054      NUMBER OF TUMORS.............			
1055 18. DEFINITIVE DIAGNOSIS..........			
 19. DATE OF INITIAL DIAGNOSIS.....: 			
 22. DIAGNOSTIC CONFIRMATON........: 			
      VASCULAR INVASION............: NA			
      BILOBAR DISEASE..............: NA			
      LYMPH NODES..................: NA			
      SIZE OF DOMINANT TUMOR (mm)..: Not performed			
      NUMBER OF TUMORS.............: Not performed			
      VASCULAR INVASION............: Unknown			
      BILOBAR DISEASE..............: Unknown			
      LYMPH NODES..................: Unknown			
23. SIZE OF TUMOR			
24. REGIONAL NODES EXAMINED			
25. REGIONAL NODES POSITIVE			
26. AJCC CLINICAL STAGE (cTNM)			
27. AJCC PATHOLOGIC STAGE (pTNM)			
28. STAGED BY			
 STAGE OF DISEASE AT DIAGNOSIS			
29 23. SIZE OF TUMOR ................			
33 24. REGIONAL NODES EXAMINED.......			
32 25. REGIONAL NODES POSITIVE.......			
 26. AJCC CLINICAL STAGE (cTNM):			
37.1      AJCC CLINICAL T..............			
37.2      AJCC CLINICAL N..............			
37.3      AJCC CLINICAL M..............			
 27. AJCC PATHOLOGIC STAGE (pTNM):			
85      AJCC PATHOLOGIC T............			
86      AJCC PATHOLOGIC N............			
87      AJCC PATHOLOGIC M............			
 28. STAGED BY:			
19      CLINICALLY STAGED BY.........			
89      PATHOLOGICALLY STAGED BY.....			
29. DATE OF FIRST COURSE OF TREATMENT			
30. DATE OF INPATIENT ADMISSION			
31. DATE OF INPATIENT DISCHARGE			
32. DATE OF NON CANCER-DIRECTED SURGERY			
33. NON CANCER-DIRECTED SURGERY			
34. DATE OF CANCER-DIRECTED SURGERY			
35. SURGICAL APPROACH			
36. SURGERY OF PRIMARY SITE			
37. RADIO-FREQUENCY DESTRUCTION OF TUMOR			
39. SURGICAL MARGINS			
40. DISTANCE OF TUMOR TO CLOSEST MARGIN			
41. SURGERY OF REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S)			
42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR			
43. RECONSTRUCTION/RESTORATION-FIRST COURSE			
44. DATE RADIATION STARTED			
45. RADIATION THERAPY			
46. DATE CHEMOTHERAPY STARTED			
48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED			
49. ROUTE CHEMOTHERAPY ADMINISTERED			
50. CHEMOTHERAPY/SURGERY SEQUENCE			
OTHER THERAPY			
51. DATE OTHER TREATMENT STARTED			
52. OTHER TREATMENT			
53. ARTERIAL EMBOLIZATION			
54. DEATH WITHIN30 DAYS OF START OF INTIIAL COURSE OF THERAPY			
 FIRST COURSE OF TREATMENT			
 29. DATE OF FIRST COURSE OF			
1 30. DATE OF INPATIENT ADMISSION...			
1.1 31. DATE OF INPATIENT DISCHARGE...			
 32. DATE OF NON CANCER-DIRECTED			
 33. NON CANCER-DIRECTED SURGERY...: 			
 34. DATE OF CANCER-DIRECTED			
 35. SURGICAL APPROACH.............: 			
 36. SURGERY OF PRIMARY SITE.......: 			
 37. RADIO-FREQUENCY DESTRUCTION OF			
1056 37. RADIO-FREQUENCY DESTRUCTION OF                                                   TUMOR........................			
 38. ABLATION & RESECTION..........: Ablation & resection not administered			
 39. SURGICAL MARGINS..............: 			
 40. DISTANCE OF TUMOR TO CLOSEST			
1058 40. DISTANCE OF TUMOR TO CLOSEST                                                     MARGIN.......................			
 41. SURGERY OF OTHER REGIONAL			
      SITE(S), DISTANT SITE(S),			
      OR DISTANT LYMPH NODE(S).....: 			
 42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR:			
      FIRST COURSE.................: 			
 44. DATE RADIATION STARTED........: 			
 45. RADIATION THERAPY.............: 			
 46. DATE CHEMOTHERAPY STARTED.....: 			
 48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:			
      CISPLATIN....................: Unknown if recommended or administered			
      FUDR.........................: Unknown if recommended or administered			
      5-FU.........................: Unknown if recommended or administered			
      FU & LEUCOVORIN..............: Unknown if recommended or administered			
      IRINOTECAN (CPT-11)..........: Unknown if recommended or administered			
      MITOMYCIN C..................: Unknown if recommended or administered			
      OXALIPLATIN..................: Unknown if recommended or administered			
      GEMCITABINE..................: Unknown if recommended or administered			
 49. ROUTE CHEMOTHERAPY ADMIN......: NA			
1069 49. ROUTE CHEMOTHERAPY ADMIN			
 50. CHEMOTHERAPY/SURGERY SEQUENCE.: No chemotherapy and/or no surgery			
 50. CHEMOTHERAPY/SURGERY SEQUENCE.: Chemotherapy before surgery			
1070 50. CHEMOTHERAPY/SURGERY SEQUENCE.			
 OTHER THERAPY			
 51. DATE OTHER TREATMENT STARTED..: 			
 52. OTHER TREATMENT...............: 			
1071 53. ARTERIAL EMBOLIZATION.........			
1072 54. DEATH WITHIN 30 DAYS OF START                                                    OF INITIAL COURSE OF THERAPY.			
55. DATE OF FIRST RECURRENCE			
56. TYPE OF FIRST RECURRENCE			
55. TYPE OF FIRST RECURRENCE			
56. DATE OF FIRST RECURRENCE			
70 55. DATE OF FIRST RECURRENCE			
71 56. TYPE OF FIRST RECURRENCE			
57. DATE OF LAST CONTACT OR DEATH			
58. VITAL STATUS			
59. CANCER STATUS			
 57. DATE OF LAST CONTACT OR DEATH..: 			
15 58. VITAL STATUS...................			
 59. CANCER STATUS..................: 			
 1. FACILITY ID NUMBER (FIN)....: 			
 2. ACCESSION NUMBER............: 			
 3. SEQUENCE NUMBER.............: 			
 4. POSTAL CODE AT DIAGNOIS.....: 			
 5. PLACE OF BIRTH..............: 			
 6. DATE OF BIRTH...............: 			
 8. SPANISH ORIGIN..............: 			
10. PRIMARY PAYER AT DIAGNOSIS..: 			
TUMOR IDENTIFICATION			
11. CLASS OF CASE...............: 			
     ORAL CONTRACEPTIVES........: 			
     ESTROGEN REPLACEMENT.......: 			
14. ALCOHOL CONSUMPTION.........: 			
15. TUMOR MARKERS:			
16. TESTS RELATED TO LIVER FUNCTION:			
    CT ARTERIAL PORTOGRAPHY:			
     VASCULAR INVASTION.........: 			
     BILOBAR DISEASE............: 			
     LYMPH NODES................: 			
     SIZE OF DOMINANT TUMOR (MM): 			
     NUMBER OF TUMORS...........: 			
    SPIRAL CT:			
    INCREMENTAL CT:			
18. DEFINITIVE DIAGNOSIS........: 			
19. DATE OF INITIAL DIAGNOSIS...: 			
22. DIAGNOSTIC CONFIRMATION.....: 			
Print Hepatocellular Cancer PCE			
STAGE OF DISEASE AT DIAGNOSIS			
23. SIZE OF TUMOR...............: 			
24. REGIONAL NODES EXAMINED.....: 			
25. REGIONAL NODES POSITIVE.....: 			
26. AJCC CLINICAL STAGE (cTNM):			
     AJCC CLINICAL T............: 			
     AJCC CLINICAL N............: 			
     AJCC CLINICAL M............: 			
     AJCC CLINICAL STAGE GROUP..: 			
27. AJCC PATHOLOGIC STAGE (pTNM):			
     AJCC PATHOLOGIC T..........: 			
     AJCC PATHOLOGIC N..........: 			
     AJCC PATHOLOGIC M..........: 			
     AJCC PATHOLOGIC STAGE GROUP: 			
28. STAGED BY:			
     CLINICALLY STAGED BY.......: 			
     PATHOLOGICALLY STAGED BY...: 			
FIRST COURSE OF TREATMENT			
29. DATE OF FIRST COURSE OF			
30. DATE OF INPATIENT ADMISSION.: 			
31. DATE OF INPATIENT DISCHARGE.: 			
32. DATE OF NON CANCER-DIRECTED			
33. NON CANCER-DIRECTED SURGERY.: 			
34. DATE OF CANCER-DIRECTED			
35. SURGICAL APPROACH...........: 			
36. SURGERY OF PRIMARY SITE.....: 			
37. RADIO-FREQUENCY DESTRUCTION			
     OF TUMOR...................: 			
39. SURGICAL MARGINS............: 			
40. DISTANCE OF TUMOR TO CLOSEST			
41. SURGERY OF OTHER REGIONAL			
     OR DISTANT LYMPH NODE(S)...: 			
     FIRST COURSE...............: 			
44. DATE RADIATION STARTED......: 			
45. RADIATION THERAPY...........: 			
46. DATE CHEMOTHERAPY STARTED...: 			
49. ROUTE CHEMOTHERAPY ADMIN....: 			
50. CHEMOTHERAPY/SURGERY SEQ....: 			
51. DATE OTHER TREATMENT STARTED: 			
52. OTHER TREATMENT.............: 			
53. ARTERIAL EMBOLIZATION.......: 			
54. DEATH WITHIN 30 DAYS OF			
     START OF INITIAL COURSE OF			
55. DATE OF FIRST RECURRENCE....: 			
56. TYPE OF FIRST RECURRENCE....: 			
57. DATE OF LAST CONTACT/DEATH..: 			
58. VITAL STATUS................: 			
59. CANCER STATUS...............: 			
The Class of Case code is not 0, 1, 2 or 5.			
The Behavior Code is not 0, 1 or 3.			
 2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors			
2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors			
10. PRIOR EXPOSURE TO RADIATION			
11. PRIMARY PAYER AT DIAGNOSIS			
12. PRIOR MEDICAL CONDITIONS			
14. GENETIC PREDISPOSITION			
15. USUAL OCCUPATION			
16. USUAL INDUSTRY			
  5. DATE OF BIRTH.................: 			
9  7. SPANISH ORIGIN................			
403 10. PRIOR EXPOSURE TO RADIATION...			
18 11. PRIMARY PAYER AT DIAGNOSIS....			
 12. PRIOR MEDICAL CONDITIONS:			
1202      MULTIPLE SCLEROSIS (MS)......			
354      MYOCARDIAL INFARCTION (MI)...			
1204      CEREBROVASCULAR DISEASE......			
1208      MALIGNANT MELANOMA...........			
1209      OTHER SKIN CANCER............			
1211      COLON OR OTHER GI CANCERS....			
 14. GENETIC PREDISPOSITION:			
1214      VON HIPPEL-LINDAU DISEASE....			
1215      TUBEROUS SCLEROSIS...........			
1216      TURCOT SYNDROME..............			
1217      LI-FRAUMENI SYNDROME.........			
1218      KOWDEN DISEASE...............			
1219      NEVOID BASAL CELL CARCINOMA..			
 15. USUAL OCCUPATION..............: 			
 16. USUAL INDUSTRY................: 			
17. CLASS OF CASE			
19. NEUROLOGICAL FINDINGS			
20. PRE-THERAPY DIAGNOSTIC STUDIES			
21. TUMOR LOCATION/INVOLVEMENT			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
